Skip to main content
Top
Published in: Hepatology International 2/2024

Open Access 21-11-2023 | Hepatitis C | Original Article

Planning, implementing, and evaluating Hepatitis C virus elimination via collaborative community-based care cascade: age–period–cohort model for estimating demand from antecedent anti-HCV survey

Authors: Ting-Yu Lin, Hsiao-Hsuan Jen, Tsung-Hui Hu, Yu-Chin Yao, Tony Hsiu-Hsi Chen, Amy Ming-Fang Yen, Yen-Po Yeh

Published in: Hepatology International | Issue 2/2024

Login to get access

Abstract

Background

Estimating the demand for HCV care cascade plays an important role in planning, monitoring, and assessing the performance of introducing a new community-based hepatitis C virus (HCV) elimination program but such an analytic and systematic approach has been barley addressed.

Methods

A new collaborative care program for HCV elimination in the Changhua Community of Taiwan has been offered to a total of 895,353 residents since 2018. To grasp the variation of demand for HCV care cascade across demographic and geographic features in the planning stage, we applied the age–period–cohort spatial model to the antecedent anti-HCV survey enrolling 123,617 participants aged 30 years or older between 2005 and 2018. Based on this precise denominator, we then employed a “before-and-after” study design to routinely evaluate whether the WHO criteria of 90% RNA positive diagnosis and 80% successful treatments could be reached.

Results

The overall demand for HCV care cascade was 4.28% (HCV infection) of the underlying population but a declining trend was noted. The early cohort had a higher demand, whereas the demand of the young cohort decreased with each passing year. The demand also differed by township. The demand, allowing for these variations, for antiviral treatment was 22,362, yielding the WHO target of 12,880 for achieving HCV elimination. With 11,844 successful treatments, the effectiveness of elimination has already reached 92% (11,844/12,880) by the end of 2022.

Conclusions

The demand for HCV care cascade allows health care decision-makers to timely and properly assess the performance of a novel community-based collaborative care program in achieving HCV elimination.
Appendix
Available only for authorised users
Literature
12.
go back to reference Palayew A, Cooke G, Hutchinson S, Razavi H, Lazarus J. Do countries have the right policies to eliminate viral hepatitis B and C: a secondary analysis of the Lancet GastroHep viral hepatitis commission. J Hepatol. 2020;73:S811CrossRef Palayew A, Cooke G, Hutchinson S, Razavi H, Lazarus J. Do countries have the right policies to eliminate viral hepatitis B and C: a secondary analysis of the Lancet GastroHep viral hepatitis commission. J Hepatol. 2020;73:S811CrossRef
13.
go back to reference Sheena BS, Hiebert L, Han H, Ippolito H, Abbasi-Kangevari M, Abbasi-Kangevari Z, et al. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796–829CrossRef Sheena BS, Hiebert L, Han H, Ippolito H, Abbasi-Kangevari M, Abbasi-Kangevari Z, et al. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796–829CrossRef
17.
go back to reference Hu TH, Su WW, Yang CC, Yang CC, Kuo WH, Chen YY, et al. Elimination of hepatitis C virus in a dialysis population: a collaborative care model in Taiwan. Am J Kidney Dis. 2021;78(4):511–519CrossRefPubMed Hu TH, Su WW, Yang CC, Yang CC, Kuo WH, Chen YY, et al. Elimination of hepatitis C virus in a dialysis population: a collaborative care model in Taiwan. Am J Kidney Dis. 2021;78(4):511–519CrossRefPubMed
18.
go back to reference Su WW, Yang CC, Chang RWJ, Yeh YH, Yen HH, Yang CC, et al. A new collaborative care approach toward hepatitis C elimination in marginalized populations. J Inf Public Health. 2023;16(8):1201–1208CrossRef Su WW, Yang CC, Chang RWJ, Yeh YH, Yen HH, Yang CC, et al. A new collaborative care approach toward hepatitis C elimination in marginalized populations. J Inf Public Health. 2023;16(8):1201–1208CrossRef
20.
go back to reference Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61(RR-4):1–32 (published correction appears in MMWR Recomm Rep. 2012 Nov 2;61(43):886)PubMed Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61(RR-4):1–32 (published correction appears in MMWR Recomm Rep. 2012 Nov 2;61(43):886)PubMed
Metadata
Title
Planning, implementing, and evaluating Hepatitis C virus elimination via collaborative community-based care cascade: age–period–cohort model for estimating demand from antecedent anti-HCV survey
Authors
Ting-Yu Lin
Hsiao-Hsuan Jen
Tsung-Hui Hu
Yu-Chin Yao
Tony Hsiu-Hsi Chen
Amy Ming-Fang Yen
Yen-Po Yeh
Publication date
21-11-2023
Publisher
Springer India
Keyword
Hepatitis C
Published in
Hepatology International / Issue 2/2024
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-023-10605-x

Other articles of this Issue 2/2024

Hepatology International 2/2024 Go to the issue

Abstracts

Abstracts

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine